Skip to main content
Premium Trial:

Request an Annual Quote

Toronto's McLaughlin Centre Awards Genomics Grants

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of Toronto's McLaughlin Centre has awarded C$650,000 ($667,900) to 10 Toronto-area research teams that are conducting genomics research in several key areas, the University said today.

Funded through the McLaughlin Centre's Accelerator Grants program, these research projects will pursue genomics studies in three areas, including genome-wide research to advance knowledge of disease genes or DNA-based diagnostics, tool development to advance clinical genomics, and studies to enhance understanding or delivery of genomic information in the healthcare system.

"Building on the original $50 million bequest from the R. Samuel McLaughlin Foundation, the McLaughlin Centre entered a new phase in 2010-2011 focusing on the advancement of genomic medicine through research and education," McLaughlin Centre Director Stephen Scherer, said in a statement. "Additional McLaughlin Centre investments of $250,000 in medical education and $150,000 in disease genome sequencing this year have kick-started a vibrant program across the University of Toronto Health Sciences complex."

The research funded under these grants involves collaborations with The Hospital for Sick Children, Toronto General Hospital, the University of Toronto, Medcan Clinic, the Samuel Lunenfeld Research Institute, and other Canadian and US partners.

These grants range from between C$50,000 and C$100,000, and fund research involving the genomic basis of congenital heart disease, mutations in genes for cardiac malformations, identifying epilepsy genes, identifying genes for early diabetes, sequence analysis studies, and others.

The university said that it plans to conduct another open grant competition in the fall of 2011.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more